Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Sponsored · Video
A Fireside Chat with Biocom President & CEO Joe Panetta
Biocom
